Anthrax – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Anthrax – Pipeline Review, H1 2017’, provides an overview of the Anthrax pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anthrax, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Anthrax

The report reviews pipeline therapeutics for Anthrax by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anthrax therapeutics and enlists all their major and minor projects

The report assesses Anthrax therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anthrax

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anthrax

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Altimmune Inc

Aphios Corp

Aradigm Corp

AtralCipan

ContraFect Corp

Crestone Inc

Dynavax Technologies Corp

Emergent BioSolutions Inc

GlaxoSmithKline Plc

Green Cross Corp

Grifols SA

Hawaii Biotech Inc

iBio Inc

Merck & Co Inc

Microbiotix Inc

NanoBio Corp

Paratek Pharmaceuticals Inc

PaxVax Inc

Pfenex Inc

PharmAthene Inc

Planet Biotechnology Inc

Protein Potential LLC

ProThera Biologics Inc

Soligenix Inc

Syntiron LLC

Tetraphase Pharmaceuticals Inc

VLP Biotech Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Anthrax - Overview 7

Anthrax - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 16

Anthrax - Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Anthrax - Companies Involved in Therapeutics Development 25

Altimmune Inc 25

Aphios Corp 25

Aradigm Corp 26

AtralCipan 26

ContraFect Corp 27

Crestone Inc 27

Dynavax Technologies Corp 28

Emergent BioSolutions Inc 28

GlaxoSmithKline Plc 29

Green Cross Corp 29

Grifols SA 30

Hawaii Biotech Inc 30

iBio Inc 31

Merck & Co Inc 31

Microbiotix Inc 32

NanoBio Corp 32

Paratek Pharmaceuticals Inc 33

PaxVax Inc 33

Pfenex Inc 34

PharmAthene Inc 34

Planet Biotechnology Inc 35

Protein Potential LLC 35

ProThera Biologics Inc 36

Soligenix Inc 36

Syntiron LLC 37

Tetraphase Pharmaceuticals Inc 37

VLP Biotech Inc 38

Anthrax - Drug Profiles 39

anthrax (virus like particles) vaccine - Drug Profile 39

anthrax + plague vaccine - Drug Profile 40

anthrax vaccine - Drug Profile 41

anthrax vaccine - Drug Profile 43

anthrax vaccine - Drug Profile 44

anthrax vaccine - Drug Profile 45

anthrax vaccine - Drug Profile 46

anthrax vaccine - Drug Profile 47

Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax - Drug Profile 48

ARD-3100 - Drug Profile 49

AV-7909 - Drug Profile 53

BDM-I - Drug Profile 55

CF-306 - Drug Profile 58

CF-307 - Drug Profile 59

CF-308 - Drug Profile 60

ciprofloxacin hydrochloride - Drug Profile 61

CPN-1311 - Drug Profile 62

DPX-Anthrax - Drug Profile 63

DV-230 - Drug Profile 65

Epimerox - Drug Profile 66

EV-035 - Drug Profile 67

GC-1109 - Drug Profile 69

gepotidacin mesylate - Drug Profile 70

GREANX - Drug Profile 73

KKL-35 - Drug Profile 74

Marinus - Drug Profile 75

Monoclonal Antibody for Anthrax - Drug Profile 76

Monoclonal Antibody for Anthrax - Drug Profile 77

Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile 78

Nasoshield - Drug Profile 79

omadacycline tosylate - Drug Profile 81

PBI-220 - Drug Profile 88

Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile 90

Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 91

Px-563L - Drug Profile 93

Px-563L Second Generation - Drug Profile 95

raxibacumab - Drug Profile 96

RiVax + SGX-204 - Drug Profile 97

rPA-01 - Drug Profile 98

RPA-563 - Drug Profile 99

Small Molecule to Inhibit DNA Helicase for Infectious Diseases - Drug Profile 100

Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia - Drug Profile 101

Small Molecules for Bacterial Infections, Skin Infections and Bone Disorders - Drug Profile 102

Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile 103

Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile 104

Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile 106

Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 107

solithromycin - Drug Profile 108

TP-271 - Drug Profile 121

Anthrax - Dormant Projects 123

Anthrax - Discontinued Products 126

Anthrax - Product Development Milestones 127

Featured News & Press Releases 127

Appendix 137

Methodology 137

Coverage 137

Secondary Research 137

Primary Research 137

Expert Panel Validation 137

Contact Us 137

Disclaimer 138

List of Tables

List of Tables

Number of Products under Development for Anthrax, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Anthrax – Pipeline by Altimmune Inc, H1 2017

Anthrax – Pipeline by Aphios Corp, H1 2017

Anthrax – Pipeline by Aradigm Corp, H1 2017

Anthrax – Pipeline by AtralCipan, H1 2017

Anthrax – Pipeline by ContraFect Corp, H1 2017

Anthrax – Pipeline by Crestone Inc, H1 2017

Anthrax – Pipeline by Dynavax Technologies Corp, H1 2017

Anthrax – Pipeline by Emergent BioSolutions Inc, H1 2017

Anthrax – Pipeline by GlaxoSmithKline Plc, H1 2017

Anthrax – Pipeline by Green Cross Corp, H1 2017

Anthrax – Pipeline by Grifols SA, H1 2017

Anthrax – Pipeline by Hawaii Biotech Inc, H1 2017

Anthrax – Pipeline by iBio Inc, H1 2017

Anthrax – Pipeline by Merck & Co Inc, H1 2017

Anthrax – Pipeline by Microbiotix Inc, H1 2017

Anthrax – Pipeline by NanoBio Corp, H1 2017

Anthrax – Pipeline by Paratek Pharmaceuticals Inc, H1 2017

Anthrax – Pipeline by PaxVax Inc, H1 2017

Anthrax – Pipeline by Pfenex Inc, H1 2017

Anthrax – Pipeline by PharmAthene Inc, H1 2017

Anthrax – Pipeline by Planet Biotechnology Inc, H1 2017

Anthrax – Pipeline by Protein Potential LLC, H1 2017

Anthrax – Pipeline by ProThera Biologics Inc, H1 2017

Anthrax – Pipeline by Soligenix Inc, H1 2017

Anthrax – Pipeline by Syntiron LLC, H1 2017

Anthrax – Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017

Anthrax – Pipeline by VLP Biotech Inc, H1 2017

Anthrax – Dormant Projects, H1 2017

Anthrax – Dormant Projects, H1 2017 (Contd..1), H1 2017

Anthrax – Dormant Projects, H1 2017 (Contd..2), H1 2017

Anthrax – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Anthrax, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports